摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

Boc-NH-CH2-CH2-Bid | 189560-91-6

中文名称
——
中文别名
——
英文名称
Boc-NH-CH2-CH2-Bid
英文别名
(1H-benzimidazol-2-yl-ethyl)carbamic acid tert-butyl ester;2-(2-(t-butyloxycarbonyl)amino)ethyl-1H-benzimidazole;tert-butyl (2-(1H-benzo[d]imidazole-2-yl)ethyl)carbamate;tert-butyl N-[2-(1H-benzimidazol-2-yl)ethyl]carbamate
Boc-NH-CH2-CH2-Bid化学式
CAS
189560-91-6
化学式
C14H19N3O2
mdl
——
分子量
261.324
InChiKey
WEFNFAHTDWNJLP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.3
  • 重原子数:
    19
  • 可旋转键数:
    5
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.43
  • 拓扑面积:
    67
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    Boc-NH-CH2-CH2-Bid盐酸 作用下, 以 乙酸乙酯 为溶剂, 以95%的产率得到2-(2-aminoethyl)benzimidazole dihydrochloride
    参考文献:
    名称:
    [EN] BENZIMIDAZOLES USEFUL AS MODULATORS OF ION CHANNELS
    [FR] BENZIMIDAZOLES CONVENANT COMME MODULATEURS DES CANAUX IONIQUES
    摘要:
    公开号:
    WO2005042497A3
  • 作为产物:
    参考文献:
    名称:
    苯并咪唑作为NOD2拮抗剂的结构特征和功能活性。
    摘要:
    NOD1和NOD2是模式识别受体,在先天免疫反应中具有重要作用。尽管它们的过度活化与多种疾病有关,但在这方面,NOD2尤其仍是未开发的靶标,仅报道了一种结构拮抗剂。为了深入了解NOD2拮抗剂的结构-活性关系,设计并合成了一系列新型类似物,然后筛选了与NOD2相对的拮抗剂活性,以及​​与NOD1相对的拮抗活性。化合物32和38被鉴定为有效的和中等选择性的NOD2拮抗剂,化合物33和42被鉴定为双重NOD1 / NOD2拮抗剂,对低微摩尔范围内的两个靶标均具有平衡的活性。
    DOI:
    10.1016/j.ejmech.2020.112089
点击查看最新优质反应信息

文献信息

  • Mitochondria‐Targeted Photoinduced Anticancer Activity of Oxidovanadium(IV) Complexes of Curcumin in Visible Light
    作者:Puja Prasad、Ila Pant、Imran Khan、Paturu Kondaiah、Akhil R. Chakravarty
    DOI:10.1002/ejic.201402001
    日期:2014.5
    Oxidovanadium(IV) complexes VO(py-aebmz)(B)]Cl (1, 2) and VO(napth-py-aebmz)(cur)]Cl 3; py-aebmz = 2-(1H-benzimidazol-2-yl)-N-(pyridin-2-ylmethylene)ethanamine, HB = acetylacetone (Hacac, 1) and curcumin (Hcur, 2), napth-py-aebmz = naphthalimide conjugated to py-aebmz ] have been prepared, characterized and their photoinduced DNA cleavage activities and photocytotoxicities studied. Complexes 1-3 each
    氧化钒(IV)配合物VO(py-aebmz)(B)]Cl (1, 2)和VO(napth-py-aebmz)(cur)]Cl 3 ;py-aebmz = 2-(1H-benzimidazol-2-yl)-N-(pyridin-2-ylmethylene)ethanamine, HB = 乙酰丙酮 (Hacac, 1) 和姜黄素 (Hcur, 2),nath-py-aebmz = 萘二甲酰亚胺已经制备、表征了与 py-aebmz 结合的 dna 分子,并研究了它们的光诱导 DNA 裂解活性和光细胞毒性。配合物 1-3 各自在 dmf/0.1 M tbap 中显示出 V-IV/V-III 氧化还原对在 -0.85 V 与 SCE 左右的不可逆循环伏安响应。该复合物通过羟基自由基和单线态氧途径在 454、530 和 647 nm 的可见光下显示出 DNA 光裂解活性。
  • Dmt-Tic di-and tri-peptidic derivatives and related compositions and methods of use
    申请人:THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVIC
    公开号:US20020161189A1
    公开(公告)日:2002-10-31
    A compound of formula: 1 wherein X is a spacer comprising one or more amino acid residues and Y comprises an aromatic group and related compositions and methods of use.
    式的化合物: 1 其中 X 是由一个或多个氨基酸残基组成的间隔物,Y 是由一个芳香基团组成的间隔物,以及相关的组合物和使用方法。
  • Synthesis, single crystal structure and efficient catalysis for alcohol oxidation of a novel Ru(II) complex with both a N,N,N-tridentate ligand and a pyridinedicarboxylate
    作者:Yuecheng Zhang、Liu Liu、Xiaohui Cao、Jiquan Zhao
    DOI:10.1016/j.poly.2015.08.047
    日期:2016.2
    A novel N,N,N-tridentate ligand known as 2-(2-pyridylmethylamino)ethylbenzimidazole (pymaeb) was designed and synthesized. This ligand in combination with disodium pyridine-2,6-dicarboxylate (pydic) reacted with RuCl3 to afford a novel complex Ru[2-(2-pyridymethylimino)ethylbenzimidazole] pyridinedicarboxylate [Ru(pymieb)(pydic)] which was characterized by NMR, IR, HR-MS and single crystal X-ray diffraction. Crystal structure analysis revealed that the complex has a distorted octahedral geometry. The complex showed excellent activity for the oxidation of various alcohols with TBHP as oxidation under mild and solvent-free conditions. (C) 2015 Elsevier Ltd. All rights reserved.
  • Evaluation of the Dmt−Tic Pharmacophore:  Conversion of a Potent δ-Opioid Receptor Antagonist into a Potent δ Agonist and Ligands with Mixed Properties
    作者:Gianfranco Balboni、Remo Guerrini、Severo Salvadori、Clementina Bianchi、Daniela Rizzi、Sharon D. Bryant、Lawrence H. Lazarus
    DOI:10.1021/jm010449i
    日期:2002.1.1
    Analogues of the 2',6'-dimethyl-L-tyrosine (Dmt)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid (Tic) pharmacophore were prepared to test the hypothesis that a "spacer" and a third aromatic center in opioid peptides are required to convert a delta-antagonist into ligands with delta-agonist or with mixed delta-antagonist/mu-agonist properties. Potent delta-agonists and bifunctional compounds with high delta- and mu-opioid receptor affinities were obtained by varying the spacer length [none, NH-CH2, NH-CH2-CH2, Gly-NH-CH2] and C-terminal aromatic nucleus [1H-benzimidazole-2-yl, phenyl (Ph) and benzyl groups]: C-terminal modification primarily affected,mu-opioid receptor affinities, which increased maximally 1700-fold relative to the prototype delta-antagonist H-Dmt-Tic-NH2 and differentially modified bioactivity. In the absence of a spacer (1), the analogue exhibited dual delta-agonism (pEC(50), 7.28) and delta-antagonism (pA(2), 7.90). H-Dmt-Tic-NH-CH2-1H-benzimidazol-2-yl (Bid) (2) became a highly potent delta-agonist (pEC(50), 9.90), slightly greater than deltorphin C (pEC(50), 9.56), with mu-agonism (pE(50), 7.57), while H-Dmt-Tic-Gly-NH-CH2-Bid (4) retained potent delta-antagonism, (pA2, 9.0) but with an order of magnitude less mu-agonism. Similarly, H-Dmt-Tic-Gly-NH-Ph (5) had nearly equivalent high mu-agonism (pEC(50), 8.52) and mu-agonism (pEC(50), -8.59), while H-Dmt-TicGly-NH-CH2-Ph (6) whose spacer was longer by a single methylene group exhibited potent delta-antagonism. (pA2, 9.25) and very high mu-agonism (pEC(50), 8.57). These data confirm that the distance between the Dmt-Tic pharmacophore and a third aromatic nucleus is an important criterion in converting Dint-Tic from a highly potent delta-antagonist into a potent delta-agonist or into ligands with mixed delta- and,mu-opioid properties.
  • VITRONECTIN RECEPTOR ANTAGONISTS
    申请人:SMITHKLINE BEECHAM CORPORATION
    公开号:EP0869787A1
    公开(公告)日:1998-10-14
查看更多